Previous 10 | Next 10 |
LEXINGTON, Mass. , Oct. 29, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter financial results on Tuesday, Novem...
The following slide deck was published by Curis, Inc. in conjunction with this Read more ...
LEXINGTON, Mass. , Sept. 26, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, Chief Executive Officer of Curis, will present at the C...
LEXINGTON, Mass. , Sept. 12, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the promotion of Bill Steinkrauss to Chief Financial Officer. Mr. Steinkrauss joined C...
LEXINGTON, Mass. , Aug. 13, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of Reinhard von Roemeling , M.D., as Senior Vice President, Clinica...
Curis, Inc. (CRIS) Q2 2019 Earnings Conference Call August 6, 2019 4:30 PM ET Company Participants Bill Steinkrauss – Vice President of Finance Jim Dentzer – President and Chief Executive Officer Bob Martell – Head of R&D Conference Call Participants ...
Curis (NASDAQ: CRIS ): Q2 GAAP EPS of -$0.22. More news on: Curis, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
LEXINGTON, Mass. , Aug. 6, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter ended June 30, 2019. "Today, we ar...
LEXINGTON, Mass. , July 30, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second quarter financial results on Tuesday, August 6,...
Finding optimum penny stocks can be tricky. There are literally thousands of options out there, but when you pick the right one, the investment can be highly rewarding. These lower-priced shares can be subject to sudden price changes with wide thresholds—this offers risk an...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Curis to Present at Upcoming Healthcare Conference in July PR Newswire LEXINGTON, Mass. , July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IR...
2024-05-25 08:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...